Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Equity Average (2017 - 2025)

Spero Therapeutics' Equity Average history spans 9 years, with the latest figure at $42.8 million for Q4 2025.

  • For Q4 2025, Equity Average fell 23.39% year-over-year to $42.8 million; the TTM value through Dec 2025 reached $42.8 million, down 23.39%, while the annual FY2025 figure was $52.6 million, 31.29% down from the prior year.
  • Equity Average reached $42.8 million in Q4 2025 per SPRO's latest filing, up from $29.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $125.4 million in Q1 2021 to a low of $29.7 million in Q3 2025.
  • Average Equity Average over 5 years is $68.7 million, with a median of $65.1 million recorded in 2023.
  • Peak YoY movement for Equity Average: surged 59.8% in 2021, then plummeted 66.16% in 2022.
  • A 5-year view of Equity Average shows it stood at $100.1 million in 2021, then tumbled by 45.84% to $54.2 million in 2022, then soared by 48.13% to $80.3 million in 2023, then crashed by 30.49% to $55.8 million in 2024, then dropped by 23.39% to $42.8 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Equity Average are $42.8 million (Q4 2025), $29.7 million (Q3 2025), and $33.3 million (Q2 2025).